trial

Omega-3 Dietary Supplements in Schizophrenia

NCTId NCT01786239
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 50 (actual)
Sponsored by Delbert Robinson
Primary completion 2015-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
50 (actual)
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Quadruple
Start
2013-05
Primary completion
2015-09
Eligibility
ALL · 15 Years · 40 Years

Interventions & indications

Drugs
RisperidoneOmega-3 capsules

Sponsors

Delbert RobinsonLead Sponsor
National Institute of Mental Health (NIMH)Collaborator
National Alliance for Research on Schizophrenia and DepressionCollaborator

Investigators

1
Delbert G. Robinson, MDPrincipal Investigator

Sites

1 total
Glen Oaks, United States

Facts & assertions

4 sourced
Enrollment
50
Phase
NA
Primary Completion Date
2015-09
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
Omega-3 capsules
drug
lead_sponsor
Delbert Robinson
company
collaborator
National Institute of Mental Health (NIMH)
company
National Alliance for Research on Schizophrenia and Depression
company
indication
Bipolar Disorder
indication
Schizophreniform Disorder
indication
Schizoaffective Disorder
indication
investigator
Delbert G. Robinson, MD
person